Table 8.

Characteristics of treatment combination tested in preclinical studies (Outcome measures).

Ref.	Outcome Measures	Findings
Wei, Huang, Fortman, Wang, Shao and Chen [39]	Skin lesions & vaccinia viral loads.	Control group: Manifested skin rashes on day 4 & developed into a mean of 1000 lesions/animal on days 9 & 12 post-challenge. Dryvax vaccinated animals: All manifested rashes on injection site on day 3 post-vaccination then developed into blisters of ~120 mm2 on day 10. Rashes continued for 18 days before scabbing. All had viral mRNA detected at days 4 & 7. Dryvax + cidofovir-treated animals: No or small rashes of <20 mm2 (p < 0.01 compared to Dryvax-alone group). Rashes healed more rapidly. 3 animals had very low level of viral mRNA.
	Dryvax-elicited antibody and T-cell immune responses	Dryvax + cidofovir caused significant reduction in Dryvax elicited antibody responses. Mean titres of titre were one log less than Dryvax alone group.